US2016331785A1PendingUtilityA1

Cells Treated by In Vitro Fucosylation and Methods of Production and Use Thereof

Assignee: OKLAHOMA MED RES FOUNDPriority: Apr 18, 2003Filed: Jul 27, 2016Published: Nov 17, 2016
Est. expiryApr 18, 2023(expired)· nominal 20-yr term from priority
A61P 7/06A61P 35/02A61P 43/00A61P 7/00C12N 5/0647C12N 5/0006A61K 35/28A61K 2035/124A61P 19/00C12N 5/0634
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated population of cells carrying on their surface a fucosylated selectin ligand, wherein the amount of fucosylated selectin ligand is sufficient to cause at least 75% of the cells in the population to bind to the selectin. 
     
     
         2 . The population of cells of  claim 1 , wherein at least 90% of the cells in the population bind to the selectin. 
     
     
         3 . The population of cells of  claim 1 , wherein at least 95% of the cells in the population bind to the selectin. 
     
     
         4 . The population of cells of  claim 1 , wherein the cells are blood cells. 
     
     
         5 . The population of cells of  claim 4 , wherein the cells are leukocytes. 
     
     
         6 . The population of cells of  claim 1 , wherein the cells are stem cells. 
     
     
         8 . The population of cells of  claim 1 , wherein the cells are produced by a process comprising the step of contacting the population of cells with an α1,3-fucosyltransferase in vitro in the presence of a fucose donor so as to fucosylate at least one glycoprotein on the surface of the population of cells to produce a fucosylated selectin ligand on the surface of the cells. 
     
     
         9 . A composition comprising:
 a therapeutically effective amount of the isolated population of cells of  claim 1 ; and   a pharmaceutically acceptable carrier.   
     
     
         10 . A therapeutic method, comprising the step of:
 administering the composition of  claim 9  to a subject in need of a treatment involving enhanced binding of the subject's cells to the selectin.   
     
     
         11 . A process of producing a population of cells exhibiting enhanced binding to a selectin, the process comprising the step of:
 contacting an isolated population of cells with an α1,3 fucosyltransferase and a fucose donor in vitro, wherein the cells have a glycoprotein on a surface thereof forms a selectin ligand when fucosylated, and wherein said contact results in fucosylation of the glycoprotein and thereby produces a population of fucosylated cells exhibiting enhanced binding to the selectin.   
     
     
         12 . The process of  claim 11 , wherein the cells are blood cells. 
     
     
         13 . The process of  claim 11 , wherein the blood cells are leukocytes. 
     
     
         14 . The process of  claim 11 , wherein the cells are stem cells. 
     
     
         15 . The process of  claim 11 , wherein the fucose donor is GDP-fucose. 
     
     
         16 . The process of  claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase III (FTIII). 
     
     
         17 . The process of  claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase IV (FTIV). 
     
     
         18 . The process of  claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase V (FTV). 
     
     
         19 . The process of  claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VI (FTVI). 
     
     
         20 . The process of  claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VII (FTVII).

Join the waitlist — get patent alerts

Track US2016331785A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.